Therapeutic effect of a MUC1-specific monoclonal antibody-drug conjugates against pancreatic cancer model.

ABSTRACT:

Background

Pancreatic cancer is one of the most aggressive malignancies without effective targeted therapies. MUC1 has emerged as a potential common target for cancer therapy because it is overexpressed in a variety of different cancers including the majority of pancreatic cancer. However, there are still no approved monoclonal antibody drugs targeting MUC1 have been reported. Recently, we generated a humanized MUC1 antibody (HzMUC1) specific to the interaction region between MUC1-N and MUC1-C. In this study, we generated the antibody drug conjugate (ADC) by conjugating HzMUC1 with monomethyl auristatin (MMAE), and examined the efficacy of HzMUC1-MMAE against the MUC1-positive pancreatic cancer in vitro and in vivo.

Methods

Western blot and immunoprecipitation were used to d

SUBMITTER: Wu G 

PROVIDER: S-EPMC9793597 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature